SpringWorks Therapeutics, Inc. (SWTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Francis I. Perier Jr., M.B.A. | Chief Financial Officer | 768.24k | -- | 1960 |
| Dr. Badreddin Edris Ph.D. | Chief Operating Officer | 1.02M | -- | 1988 |
| Dr. James Cassidy M.D., Ph.D. | Chief Medical Officer | 904.25k | -- | 1960 |
| Mr. Michael P. Nofi | Chief Accounting Officer | -- | -- | 1971 |
| Mr. Tai-An Lin Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Kim Diamond | Vice President of Communications & Investor Relations | -- | -- | -- |
| Mr. Herschel S. Weinstein J.D. | General Counsel & Secretary | 568.64k | -- | 1957 |
| Mr. Daniel J. Pichl | Chief People Officer | 428.51k | -- | 1984 |
| Mr. Bhavesh Ashar M.B.A. | Chief Commercial Officer | 729.62k | -- | 1966 |
SpringWorks Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 305
Description
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
Corporate Governance
Recent Events
- Apr 05, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Feb 27, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 02, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 26, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 23, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing